Hope it wo_老虎社区_美港股上老虎

AshleySpace
2021-10-04

Hope it works as they claims

Merck extends gains after data for COVID-19 pill as vaccine makers retreat

After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark

Merck extends gains after data for COVID-19 pill as vaccine makers retreat

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":820349583,"tweetId":"820349583","gmtCreate":1633355535058,"gmtModify":1633355627607,"author":{"id":3578886966105998,"authorId":3578886966105998,"authorIdStr":"3578886966105998","name":"AshleySpace","avatar":"https://static.tigerbbs.com/86ceb5655988ed5ab92e6a5a06450942","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hope it works as they claims</p></body></html>","htmlText":"<html><head></head><body><p>Hope it works as they claims</p></body></html>","text":"Hope it works as they claims","highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/820349583","repostId":1140558350,"repostType":4,"repost":{"id":"1140558350","pubTimestamp":1633355202,"share":"https://www.laohu8.com/m/news/1140558350?lang=&edition=full","pubTime":"2021-10-04 21:46","market":"us","language":"en","title":"Merck extends gains after data for COVID-19 pill as vaccine makers retreat","url":"https://stock-news.laohu8.com/highlight/detail?id=1140558350","media":"seekingalpha","summary":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-mark","content":"<ul>\n <li>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading&nbsp;~4.0% higher,&nbsp;with ~1.8 million shares changing hands.</li>\n <li>Meantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.</li>\n <li>In an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.</li>\n <li>Moderna (MRNA) and BioNTech (BNTX) are notable decliners, trading&nbsp;~5.1% and ~6.0% lower,&nbsp;while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has&nbsp;lost ~6.3%&nbsp;after sliding ~26.8% last week to rank among the&nbsp;worst performers in healthcare.</li>\n <li>However, Pfizer (PFE) and Johnson &amp; Johnson(NYSE:JNJ)are trading flat, with&nbsp;losses standing at ~0.8% and ~0.1%&nbsp;in the pre-market.</li>\n <li>Pfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.</li>\n <li>Meanwhile,<i>TheNew York Times</i>&nbsp;reported today that Johnson &amp; Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.</li>\n</ul>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck extends gains after data for COVID-19 pill as vaccine makers retreat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck extends gains after data for COVID-19 pill as vaccine makers retreat\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-04 21:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine ...</p>\n\n<a href=\"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3748031-merck-extends-gains-after-data-for-covid-19-pill-as-vaccine-makers-retreat","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140558350","content_text":"After reaching a 52-week high on Friday, Merck(NYSE:MRK)continues its winning streak in the pre-market trading ~4.0% higher, with ~1.8 million shares changing hands.\nMeantime, the established vaccine makers, notably, BioNTech(NASDAQ:BNTX), the partner of Pfizer(NYSE:PFE)for the first COVID-19 vaccine approved in the U.S., and Moderna(NASDAQ:MRNA), have extended their losses.\nIn an interim analysis of a late-stage trial involving patients with mild-to-moderate COVID-19, Merck’s drug molnupiravir developed in partnership with Ridgeback Biotherapeutics, was found to have cutthe risk of hospitalization or death by 50%.\nModerna (MRNA) and BioNTech (BNTX) are notable decliners, trading ~5.1% and ~6.0% lower, while the COVID-19 vaccine developer Novavax(NASDAQ:NVAX)has lost ~6.3% after sliding ~26.8% last week to rank among the worst performers in healthcare.\nHowever, Pfizer (PFE) and Johnson & Johnson(NYSE:JNJ)are trading flat, with losses standing at ~0.8% and ~0.1% in the pre-market.\nPfizer’s (PFE) own experimental oral COVID-19 therapy PF-07321332 is undergoing a Phase 2/3 study in combination with a low dose of ritonavirfor the prevention of COVID-19.\nMeanwhile,TheNew York Times reported today that Johnson & Johnson (JNJ) is planning to seek regulatory authorization for its COVID-19booster shot early this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":410,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["HOPE"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":23,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Merck extends gains after data for COVID-19 pill as vaccine makers retreat

评论（3）

热议股票